RECRUITINGOBSERVATIONAL
Serial Assessment of Fertility Experiences
A Prospective Longitudinal Study of Growth, Development, Fertility and Reproductive Outcomes Among Adolescents and Young Adults With Sickle Cell Anemia With Hydroxyurea
About This Trial
The SAFE study is a long-term research project that watches people with sickle cell anemia (SCA) over time. The main goal is to see how a medicine called hydroxyurea affects their growth, puberty, and ability to have children. A second goal is to see how hydroxyurea affects pregnancy outcomes, by comparing people who take the medicine to those who don't.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with documented sickle cell anemia (SCA).
- At least 8 years of age at the time of enrollment.
- Enrolled on the EXTEND or SACRED study.
- Provide willing to sign a consent form.
- Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Who Should NOT Join This Trial:
- Currently taking part in another treatment study (not EXTEND or SACRED).
- Has received other treatments for sickle cell disease in the past 6 months.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with documented sickle cell anemia (SCA).
* At least 8 years of age at the time of enrollment.
* Enrolled on the EXTEND or SACRED study.
* Provide informed consent.
* Able to take part in all parts of the study, including treatments, check-ups, and follow-up visits.
Exclusion Criteria:
* Currently taking part in another treatment study (not EXTEND or SACRED).
* Has received other treatments for sickle cell disease in the past 6 months.
Locations (3)
Centro de Obstetricia y Ginecologia
Santo Domingo, Dominican Republic
Caribbean Institute for Health Research, University of West Indies
Kingston, Jamaica
Buganda Medical Centre
Mwanza, Tanzania